10.31
-0.34 (-3.19%)
| 前收盘价格 | 10.65 |
| 收盘价格 | 10.61 |
| 成交量 | 2,853,420 |
| 平均成交量 (3个月) | 2,439,559 |
| 市值 | 1,279,172,096 |
| 市盈率 (P/E TTM) | 51.55 |
| 预期市盈率 (P/E Forward) | 29.50 |
| 价格/销量 (P/S) | 4.96 |
| 股市价格/股市净资产 (P/B) | 2.14 |
| 52周波幅 | |
| 利润日期 | 6 May 2025 - 12 May 2025 |
| 营业毛利率 | 9.85% |
| 营业利益率 (TTM) | 0.80% |
| 稀释每股收益 (EPS TTM) | 0.200 |
| 季度收入增长率 (YOY) | 29.60% |
| 季度盈利增长率 (YOY) | 3,119.20% |
| 总债务/股东权益 (D/E MRQ) | 42.63% |
| 流动比率 (MRQ) | 10.80 |
| 营业现金流 (OCF TTM) | 66.51 M |
| 杠杆自由现金流 (LFCF TTM) | 49.10 M |
| 资产报酬率 (ROA TTM) | 0.06% |
| 股东权益报酬率 (ROE TTM) | 4.48% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
| 股票 | Dynavax Technologies Corporatio | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.63 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 内部持股比例 | 0.48% |
| 机构持股比例 | 107.36% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Chicago Capital, Llc | 31 Mar 2025 | 5,344,570 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 33.00 (Citizens Capital Markets, 220.08%) | 购买 |
| 中 | 31.00 (200.68%) | |
| 低 | 10.00 (Goldman Sachs, -3.01%) | 卖出 |
| 平均值 | 24.67 (139.28%) | |
| 总计 | 2 购买, 1 卖出 | |
| 平均价格@调整类型 | 12.32 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 10.00 (-3.01%) | 卖出 | 10.31 |
| 11 Feb 2025 | 12.00 (16.39%) | 卖出 | 12.70 | |
| Citizens Capital Markets | 21 Feb 2025 | 33.00 (220.08%) | 购买 | 13.33 |
| HC Wainwright & Co. | 21 Feb 2025 | 31.00 (200.68%) | 购买 | 13.33 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合